R&D Center

NPO Petrovax Pharm’s concept is based on delivering original products. The company has an in-house R&D Center, and annually invests in R&D projects associated with new products.

The company holds more than 20 world patents for molecules, inventions, and pharmaceutical manufacturing processes.

The R&D Department structure provides for managing the molecule inception and product lifecycle from the idea to implementation in medical practice. Ad hoc studies are conducted with participation of leading domestic and foreign research institutions.

Areas of business

Innovative search for promising candidate molecules with subsequent assessment of their safety and specific activity

Studying mechanisms of action of development products in disease process

Safety profile and efficacy assay of a pharmaceutical product-to-be in preclinical setting

Development of quality control methods, and manufacturing processes

Planning and conducting pivotal clinical studies

Implementation of technological processes; upgrading and optimization of current processes; and production scaling

Presently, there are more than ten innovative products at different development stages in the company’s pipeline.

In the coming years, NPO Petrovax Pharm plans to launch to the market a new polymer combined medication to treat intoxication caused by different factors as well as three sustained release biopharmaceuticals with improved pharmacological properties based on recombinant therapeutic proteins to treat hepatitis B and C, anemia in chronic renal failure and cancer patients, and rheumatoid arthritis.

A quadrivalent adjuvant influenza vaccine effectively protecting against four influenza virus strains, with maximum safety profile, will be available on the market in 2018.